Ceragon Networks (CRNT) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.05 per share a year ago.

Dayforce (DAY) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.43 per share a year ago.

Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago.

Hain Celestial (HAIN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.13 per share a year ago.

Hagerty, Inc. (HGTY) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.04 per share a year ago.

Forge Global Holdings, Inc. (FRGE) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $1.50 per share a year ago.

Tariffs have become the new constituency of "higher-for-longer" scenario. It is hard to imagine how we could revert back to the same tariff levels that were in force before Trump took the Office. All of this comes with its own set of positives and negatives.

BEVERLY, Mass. , May 7, 2025 /PRNewswire/ -- Tobin Scientific, a leading provider of cGMP storage, biorepository services, and specialized logistics for the life sciences industry, announced today that it has closed a significant capital raise to support its next phase of growth.

Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical Guidance Click here to access replay of company's April 30, 2025 investor webcast SAN FRANCISCO, CA / ACCESS Newswire / May 7, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today provided an overview of expected Q2 - Q4 2025 catalysts related to potential follow-on indications for crofelemer, the company's novel plant-based prescription drug approved by the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER). "As discussed during Jaguar's investor webcast last week, 2025 is a year of catalysts …

Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 LA JOLLA, CA, May 07, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that enrollment for the 6 week interim analysis is complete with 24 of the 36 planned …

MELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Vice President of Research and Development, Francisco Silva, will present an update on its ongoing Phase 2 clinical trial of BRTX-100 in chronic lumbar disc disease (cLDD) at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting, taking place May 7 - 10, 2025 in New Orleans, LA.

April same-store sales increased 4.3% year-over-year * NEWARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- NRSInsights, a provider of sales data and analytics drawn from retail transactions processed through the National Retail Solutions (NRS) point-of-sale (POS) platform, today announced comparative retail same-store sales results for April 2025.

SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- On May 1, 2025, investors in SelectQuote (NYSE: SLQT) saw the price of their shares tumble over 19% after the U.S. Department of Justice announced it had filed a lawsuit against the company, other insurance brokers, and three of the nation's largest health insurance companies, claiming violations of the False Claims Act.

NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your BigBear.ai Holdings, Inc. (NYSE:BBAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bigbear-ai-holdings-inc-lawsuit-submission-form?prid=147299&wire=1 or contact Joseph E. Levi, Esq.

The latest trade tariff rollouts by President Trump have hit the technology sector of the United States harder than most expected. The reason is that the tariffs seem to be centered around semiconductors and chipmakers in Asian regions, which consequently hold most of the industry's supply and logistics chain.

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.

Palmer Square Capital BDC Inc. (PSBD) came out with quarterly earnings of $0.40 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.52 per share a year ago.

Rockwell Automation (ROK) came out with quarterly earnings of $2.45 per share, beating the Zacks Consensus Estimate of $2.09 per share. This compares to earnings of $2.50 per share a year ago.

Dine Brands (DIN) came out with quarterly earnings of $1.03 per share, missing the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.33 per share a year ago.

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago.